FindTrial
Sign In

Reduced antithrombotic strategy for high bleeding risk patients with myocardial infarction treated with percutaneous coronary intervention - The Dan-DAPT trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-500125-32-00
Acronym
2022-500125-32-00
Enrollment
2700
Registered
2022-04-27
Start date
2022-06-20
Completion date
Unknown
Last updated
2025-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial infarction

Brief summary

The primary composite endpoints are: • The NACE (net adverse clinical events) endpoint is a composite of all-cause mortality, recurrent myocardial infarc, definite stent thrombosis, ischemic stroke, and BARC type 3-5 non-access site bleedings after 12 months • Bleeding Academic Research Consortium (BARC) type 2-5 non-access site bleeding after 12 months

Interventions

DRUGEfient 10 mg film-coated tablets.
DRUGEfient 5 mg film-coated tablets.
DRUGBrilique 90 mg film-coated tablets
DRUGACETYLSALICYLIC ACID
DRUGCLOPIDOGREL
DRUGPrasugrel "Krka"
DRUGfilmovertrukne tabletter
DRUGPrasugrel Teva 5 mg Film-coated Tablets
DRUGPrasugrel Mylan 10 mg film-coated tablets
DRUGPrasugrel Teva 10 mg Film-coated Tablets
DRUGPrasugrel Mylan 5 mg film-coated tablets

Sponsors

Rigshospitalet
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary composite endpoints are: • The NACE (net adverse clinical events) endpoint is a composite of all-cause mortality, recurrent myocardial infarc, definite stent thrombosis, ischemic stroke, and BARC type 3-5 non-access site bleedings after 12 months • Bleeding Academic Research Consortium (BARC) type 2-5 non-access site bleeding after 12 months—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 5, 2026